Get the Stockscreener App
106.38
0.97%
-1.04
After Hours:
111.00
4.62
+4.34%
Guardant Health Inc stock is traded at $106.38, with a volume of 1.62M.
It is down -0.97% in the last 24 hours and down -5.14% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$107.42
Open:
$106.61
24h Volume:
1.62M
Relative Volume:
0.80
Market Cap:
$13.82B
Revenue:
$902.57M
Net Income/Loss:
$-398.79M
P/E Ratio:
-33.11
EPS:
-3.2131
Net Cash Flow:
$-274.52M
1W Performance:
+3.52%
1M Performance:
-5.14%
6M Performance:
+81.63%
1Y Performance:
+117.10%
1-Day Range:
$104.90
$108.85
1-Week Range:
$102.00
$110.46
52-Week Range:
$34.88
$120.74
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
106.38 | 13.95B | 902.57M | -398.79M | -274.52M | -3.2131 |
|
TMO
Thermo Fisher Scientific Inc
|
515.12 | 192.95B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
211.25 | 147.43B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
630.73 | 50.70B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
126.34 | 35.90B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
328.66 | 32.13B | 3.17B | 642.63M | 539.81M | 10.77 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health earnings up next: Can Shield growth offset losses? By Investing.com - Investing.com Canada
GSA Capital Partners LLP Increases Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health (NASDAQ:GH) Rating Increased to Strong-Buy at Robert W. Baird - MarketBeat
Guardant Health, Inc. $GH Shares Bought by Eagle Health Investments LP - MarketBeat
Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow - Finviz
Guardant Health Q4 2025 Earnings Report Date & Analyst ForecastsNews and Statistics - IndexBox
What Makes Guardant Health (GH) a Good Healthcare Holding - Finviz
Guardant Health (GH): Baird Initiates Coverage with Outperform R - GuruFocus
Baird initiates Guardant Health stock coverage with outperform rating By Investing.com - Investing.com South Africa
Baird initiates Guardant Health stock coverage with outperform rating - Investing.com
North America Liquid Biopsy Market to Reach US$ 5110.34 Million - openPR.com
Guardant Health, Inc. (GH) Stock Analysis: Riding the 19.45% Potential Upside in Precision Oncology - DirectorsTalk Interviews
Published on: 2026-02-14 21:22:46 - mfd.ru
A Look At Guardant Health (GH) Valuation As New ctDNA Study Supports Guardant Reveal In Colon Cancer - Yahoo Finance
Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why (GH) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Cancer Profiling Market Size, Share | Growth Report [2034] - Fortune Business Insights
Top Cancer Stocks for 2026 and How to Invest - The Motley Fool
Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open - Yahoo Finance
GoFundMe for James Van Der Beek’s family surpasses $1.5M in less than 24 hours - Austin American-Statesman
Guardant Health Shares Slide as Principal Cuts Stake and Insiders Sell - CryptoRank
Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Guardant Health, Inc. $GH Shares Sold by Principal Financial Group Inc. - MarketBeat
Travel Stocks: How does Guardant Health Inc compare to its peersJuly 2025 Levels & Fast Gain Swing Alerts - baoquankhu1.vn
Guardant Health (GH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Guardant Health Inc (GH) Trading Down 4.5% on Feb 11 - GuruFocus
Minimal Residual Disease Testing Market Poised for Rapid Growth - openPR.com
Aug Momentum: Is now the right time to enter Guardant Health IncJuly 2025 Fed Impact & Verified Stock Trade Ideas - baoquankhu1.vn
New York State Common Retirement Fund Has $4.77 Million Stake in Guardant Health, Inc. $GH - MarketBeat
IQ EQ FUND MANAGEMENT IRELAND Ltd Lowers Position in Guardant Health, Inc. $GH - MarketBeat
A Congress Member Sold Up To $125K In McDonald's Stock: Here's What You Need To Know - Benzinga
ETF Watch: Is now the right time to enter Guardant Health Inc2025 Volume Leaders & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Guardant Health to Participate in Upcoming Investor ConferencesFebruary 3, 2026 - BioSpace
Precision oncology firm Guardant lines up four investor talks - stocktitan.net
Guardant Health ctDNA test sets new standard in cancer detection - Traders Union
Guardant Health guides Q4 and FY25 revenue above consensus - MSN
Understanding Momentum Shifts in (GH) - Stock Traders Daily
Merck Eyes Post Keytruda Growth With Eikon Stake And Guardant Pact - Yahoo Finance
Guardant Health (GH) Study Highlights Advancements in Colon Canc - GuruFocus
Guardant Health, Inc. (GH) Stock Analysis: A Precision Oncology Pioneer with 9.82% Upside Potential - DirectorsTalk Interviews
ctDNA blood test better predicts colon cancer recurrence than standard staging - Investing.com
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions - Business Wire
Blood test flags colon cancer patients most likely to see disease return - Stock Titan
Aug Intraday: Can Guardant Health Inc benefit from deglobalizationWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
Knights of Columbus Asset Advisors LLC Takes Position in Guardant Health, Inc. $GH - MarketBeat
Assessing Guardant Health (GH) Valuation After FDA Guardant360 CDx Approval And New Merck Collaboration - Yahoo Finance
UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating - marketscreener.com
Should You Buy Guardant Health Before Feb. 19? - The Globe and Mail
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Business Wire
Guardant Health, Inc. $GH Shares Bought by Federated Hermes Inc. - MarketBeat
Merger Talk: What are the future prospects of Guardant Health IncWeekly Loss Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):